MGMaría Luisa Guevara-Fujita

María Luisa Guevara-Fujita

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


María Luisa Guevara-Fujita has a total of 309 co-authors. Here are the top co-authors by number of shared publications:

  • Ricardo Fujita

    Universidad de San Martín de Porres, Peru

    11 shared publications
  • Oscar Acosta

    Centro de Genética y Biología Molecular, Facultad de Medicina Humana, Universidad de San Martin de Porres, Lima 15024, Peru

    7 shared publications
  • Daisy Obispo

    Centro de Genética y Biología Molecular, Facultad de Medicina Humana, Universidad de San Martin de Porres, Lima 15024, Peru

    4 shared publications
  • Alexis Germán Murillo Carrasco

    Center for Translational Research in Oncology (LIM24), Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), São Paulo 01246-000, Brazil, São Paulo, Brazil

    3 shared publications
  • Ricardo Fujita

    Centro de Genetica y Biologia Molecular, Facultad de Medicina Humana, Universidad de San Martin de Porres. Lima, Peru

    3 shared publications
  • Teodoro J. Oscanoa

    Universidad de San Martín de Porres, Facultad de Medicina Humana, Centro de Investigación de Seguridad del Medicamento. Lima, Perú. Universidad Nacional Mayor de San Marcos, Facultad de Medicina. Lima, Perú

    3 shared publications

Latest Publications

  • Open Access

    Plasma hsa-miRNA-145 Levels in Peruvian Women: In Silico Analysis and Inferences for Breast Cancer

    by Oscar Acosta, Angelo Motta, Jose Buleje, Alexis Murillo-Carrasco, Daisy Obispo, Luisa Negron, Joseph Pinto, Maria Guevara, Ricardo Fujita

    MicroRNAs (miRNAs) are small non-coding sequences that regulate gene expression at the post-transcriptional level in various biological processes (including differentiation, cell proliferation, cell cycle and apoptosis). Low levels of human miRNA-145 (hsa-miRNA-145) expression have been found in the plasma of cancer patients, suggesting that it is a tumor suppressor. Newly developed molecular biology technologies such as digital PCR (dPCR) have high sensitivity and specificity for evaluating miRNAs, with potential value for hsa-miRNA-145 analyses. This study involved the evaluation of circulating hsa-miRNA-145 levels in the plasma of Peruvian women using digital dPCR, along with in silico analysis of its metabolic impact on cancer. This study included plasma samples from 30 women residing in Lima (aged 20–67). All individuals had previously received negative breast cancer screening results between 2016 and 2018. We used a chip-based amplification platform (dPCR system) to analyze their hsa-miRNA-145 levels and compare them with those reported in breast cancer patients. These patients had significantly lower levels. In the in silico analysis, 35 target transcripts belonging to signaling and metabolic pathways associated with the variation in hsa-miRNA-145 levels in breast and ovarian cancer were identified. Specifically, hsa-miRNA-145 was predicted to significantly impact calcium, cell proliferation, metastasis, and glucose/glutamine metabolism, with effects on the CAMK2D, EGFR, TP53, hexokinase 2 (HK2), and glutaminase (GLS) genes. This research deepens our understanding of the epigenetic factors involved in breast cancer, including plasma miRNA-145 levels, as well as associated metabolic pathways, which could promote precision medicine for Peruvian cancer patients.


  • Open Access

    Asociación entre el gen NAT2 y la lesión hepática inducida por pirazinamida en pacientes peruanos con tuberculosis

    by Teodoro Julio Oscanoa Espinoza, María L. Guevara-Fujita, Oscar Acosta, Saul Moscol, Ricardo M. Fujita

    Introducción: El gen de la N-acetiltransferasa 2 (NAT2) ha sido ampliamente estudiado por su asociación con la Injuria hepática inducida por medicamentos causada por fármacos antituberculosos. El objetivo del presente estudio es evaluar la asociación entre seis polimorfismos del gen NAT2 y la Injuria hepática inducida por pirazinamida (IHIP) en pacientes peruanos. Material y métodos: La asociación específica con IHIP se determinó mediante procesos como reexposición, suspensión y recuperación. Se estudiaron seis polimorfismos del gen NAT2: rs1799929 (c.481C>T), rs1799930 (c.590G>A), rs1799931 (c.857G>A), rs1041983 (c.282C>T), rs1801280 (c.341T>C) y rs1208 (c.802G>A). Resultados: Se incluyeron en el estudio cuarenta pacientes (10 casos y 30 controles) con tuberculosis. Para el polimorfismo rs1041983 (c.282C>T), la razón de probabilidades (OR) fue de 3,7 (IC del 95 %: 1,3-10,6) cuando se analizó C vs T, lo que indica una asociación y un riesgo de IHIP con el alelo T. Además, para el polimorfismo rs1208 (c.802G>A), la OR fue de 3,2 (IC del 95 %: 1,0-10,0) para A vs G, lo que indica una asociación y un riesgo de IHIP con el alelo A. No se encontró asociación significativa con los demás polimorfismos de NAT2 estudiados. Conclusión: La evaluación de seis polimorfismos del gen NAT2 indica una probable asociación entre rs1041983 (c.282C>T) y rs1208 (c.802G>A) y IHIP en pacientes peruanos con tuberculosis.

  • Open Access

    New Associations with the HIV Predisposing and Protective Alleles of the Human Leukocyte Antigen System in a Peruvian Population

    by Daisy Obispo, Oscar Acosta, Maria L. Guevara, Susan Echavarría, Susan Espetia, María Dedios, Carlos Augusto Yabar, Ricardo Fujita

    The accurate determination of an individual’s unique human leukocyte antigen (HLA) allele holds important significance in evaluating the risk associated with autoimmune and infectious diseases, such as human immunodeficiency virus (HIV) infection. Several allelic variants within the HLA system have been linked to either increased protection or susceptibility in the context of infectious and autoimmune diseases. This study aimed to determine the frequency and association of HLA alleles between people living with HIV (PLHIV) as the case group and Peruvian individuals without HIV with high-risk behaviors of sexually transmitted diseases as the control group. Whole exome sequencing (WES) was used to determine high-resolution HLA allelotypes using the OptiType and arcas HLA tools. The HLA alleles present in HLA classes I (A, B, and C loci) and II (DPB1, DQA1, DQB1, and DRB1 loci) were determined in a cohort of 59 PLHIV (cases) and 44 individuals without HIV (controls). The most frequent HLA alleles were A*02:01, DPB1*04:02, and DQB1*03:419 at 36%, 30%, and 28% prevalence in general population. We found that C*07:01 (p = 0.0101; OR = 10.222, 95% IC: 1.40–74.55), DQA1*03:02 (p = 0.0051; OR = 5.297, 95% IC: 1.48–19.02), and DRB1*09:01 (p = 0.0119; OR = 4.788, 95% IC: 1.39–16.44) showed an association with susceptibility to HIV infection, while DQB1*03:419 (p = 0.0478; OR = 0.327, 95% IC: 0.11–0.96) was associated with protection from HIV infection. Our findings contribute to the knowledge of HLA allele diversity in the Peruvian population (around 70% South American indigenous ancestry) lays the groundwork for further valuable large-scale use of HLA typing and offers a novel association with HIV infection that is relevant to vaccine studies.


  • Open Access

    Variants in the N-acetyltranferase 2 gene, acetylator phenotypes and their association with tuberculosis: Findings in Peruvian patients

    by Rodrigo Sánchez, Oscar Acosta, Lina Laymito, Teodoro Oscanoa, María Guevara-Fujita, Saul Moscol, Daisy Obispo, Doris Huerta, Ricardo Fujita


  • Open Access

    New Associations with HIV Predisposing and Protective Alleles of the HLA System in a Peruvian Population

    by Daisy Obispo, Oscar Acosta, Maria Guevara, Susan Echavarria, Susan Espetia, Maria Dedios, Carlos Yábar, Ricardo Fujita

    Accurate determination of an individual’s unique human leukocyte antigen (HLA) allele holds important significance in evaluating the risk associated with autoimmune and infectious diseases, such as human immunodeficiency virus (HIV) infection. Several allelic variants within the HLA system have been linked to either increased protection or susceptibility in the context of infectious and autoimmune diseases. This study aimed to determine the frequency and association of HLA alleles between people living with HIV (PLHIV) as the case group and HIV-uninfected Peruvian individuals with high-risk behavior of sexual transmission diseases as the control group. Whole exome sequencing (WES) was used to determine high-resolution HLA allelotypes using OptiType and arcasHLA tools. The HLA alleles present in HLA classes I (A, B, and C loci) and II (DPA1, DPB1, DQA1, DQB1 and DRB1 loci) were determined in a cohort of 59 PLHIV (cases) and 44 HIV-uninfected individuals (controls). The most frequent HLA alleles were A*02:01, DPB1*04:02 and DQB1*03:419 at 36%, 30% and 28% prevalence in general population. We found that C*07:01 (p = 0.0101; OR = 10.222, 95% IC: 1.40–74.55), DQA1*03:02 (p = 0.0051; OR = 5.297, 95% IC: 1.48–19.02) and DRB1*09:01 (p = 0.0119; OR = 4.788, 95% IC: 1.39–16.44) showed an association with susceptibility to HIV infection, while DQB1*03:419 (p = 0.0478; OR = 0.327, 95% IC: 0.11–0.96) was associated with protection from HIV infection. Our findings contribute to the knowledge of HLA allele diversity in the Peruvian population (around 70% South American indigenous ancestry), lay the groundwork for further valuable large-scale use of HLA typing and offer a novel association of HIV infection that is relevant to vaccine studies.

  • Open Access

    Whole exome sequencing in a sample of Peruvian patients diagnosed with epidermolysis bullosa

    by Alejandro Zevallos-Morales, Rosario Torres Iberico, Daisy Obispo, Pierina Danos, Rodrigo M Sanchez, Ricardo Fujita, Maria L Guevara-Fujita

    Background: Epidermolysis bullosa (EB) is a complex and heterogeneous dermatological disease. Four main types of EB have been described, each of them with distinct characteristics: EB simplex (EBS), dystrophic EB (DEB), junctional EB (JEB) and Kindler EB (KEB). Each main type varies in its manifestations, severity, and genetic abnormality. Methods: We sought mutations in 19 genes known to cause EB and 10 genes associated with other dermatologic diseases in 35 Peruvian pediatric patients of a rich Amerindian genetic background. Whole exome sequencing and bioinformatics analysis was performed. Results: Thirty-four of 35 families revealed an EB mutation. Dystrophic EB was the most frequently diagnosed type, with 19 (56%) patients, followed by EBS (35%), JEB (6%), and KEB (3%). We found 37 mutations in seven genes; 27 (73%) were missense mutations; 22 (59%) were novel mutations. Five cases changed their initial diagnosis of EBS. Four were reclassified as DEB and one as JEB. Inspection into other non-EB genes revealed a variant, c.7130C>A, in the gene FLGR2, which was present in 31 of the 34 patients (91%). Conclusion: We were able to confirm and identify pathological mutations in 34 of 35 patients.


  • Open Access

    MLPA followed by target‐NGS to detect mutations in the dystrophin gene of Peruvian patients suspected of DMD/DMB

    by María Luisa Guevara‐Fujita, Francia Huaman‐Dianderas, Daisy Obispo, Rodrigo Sánchez, Victor Barrenechea, Diana Rojas‐Málaga, Alejandro Estrada‐Cuzcano, Milana Trubnykova, Mario Cornejo‐Olivas, Victoria Marca, et al.

    Background: We report the molecular analysis of the DMD gene in a group of Peruvian patients with Duchenne/Becker dystrophinopathy. This is the first study to thoroughly characterize mutations in this population.Methods: We used the combination of multiplex ligation‐dependent probe amplification (MLPA) and sequencing analysis of the DMD gene. We recruited Peruvian patients in 2 years from reference national hospitals. We performed DNA tests in 152 patients, checking first exon deletion/duplication by MLPA, and subsequently, if negative, samples were sequenced to detect point mutations.Results: The average age for diagnosis was 9.8 years, suggesting a delay for timely diagnosis and care. We found causal DMD mutations in 125 patients: 72 (57.6%) exon deletions/duplications (41.6% deletions, 16.0% duplications), and 53 (42.4%) point mutations (27.2% nonsense, 9.6% small indels, and 5.6% splice site).Conclusion: Due to our genetic background, we expected a higher number of novel and recurrent causal mutations in our sample. Results showed 16% of novel mutations, similar to other well‐studied populations.


  • Angiotensin-Converting Enzyme (ACE) genetic variation and longevity in Peruvian older people: a cross-sectional study

    by Teodoro J. Oscanoa, Edwin C. Cieza, Frank A. Lizaraso-Soto, María L. Guevara, Ricardo M. Fujita, Román Romero-Ortuño

    Background: Some studies have suggested that the insertion(I)/deletion(D) polymorphism of the Angiotensin-Converting Enzyme (ACE) gene may be associated with human longevity, especially in centenarians. However, this association is still controversial. Besides, there have been no studies in Peruvians. Aim: To describe the age distribution of the ACE polymorphism in a convenience sample of Peruvian older people. Subjects and methods: This was a cross-sectional study in 104 Geriatric Day Hospital patients in Lima, Perú. The ACE polymorphism was determined in all patients. For the purpose of association with age, the sample was divided into four categories: young (< 65), youngest-old (65–74), middle-old (75–84) and oldest-old (85 or more). Results: The distribution of genotype frequencies was consistent with a population in Hardy-Weinberg equilibrium (p = 0.62). The number (%) of D/D, I/D and I/I genotypes in the young was 2 (14.3%), 3 (21.4%) and 9 (64.3%), respectively; in youngest-old: 4 (11.4%), 15 (42.9%) and 16 (45.7%); in middle-old: 6 (12.2%), 20 (40.8%) and 23 (46.9%); and in oldest-old: 0 (0.0%), 4 (66.7%) and 2 (33.3%). A chi-square analysis showed no significant differences in genotype distribution between age groups (p = 0.647). Conclusion: No significant age differences were found in the distribution of the ACE polymorphism in this sample. Further studies with greater statistical power are recommended.


  • Open Access

    Novel mutation in ENG gene causing Hereditary Hemorrhagic Telangiectasia in a Peruvian family

    by Alejandro Zevallos-Morales, Alexis Murillo, Milagros M. Dueñas-Roque, Ana Prötzel, Luis Venegas-Tresierra, Verónica Ángeles-Villalba, Miguel Guevara-Cruz, Ada Chávez-Gil, Ricardo Fujita, Maria L. Guevara-Fujita

    Patients with HHT can suffer from a plethora of symptoms. Usually, they manifest with recurrent epistaxis and telangiectasias but can also present more severe symptoms as anemia, gastrointestinal bleeding and complications due to AVMs in the brain, liver or lungs (McDonald et al., 2011). The diagnosis of HHT is made using the Curaçao criteria that consist of epistaxis, telangiectasias, visceral lesions and family history; to diagnose it, three of the four Curaçao criteria should be present (Faughnan et al., 2011).


  • Open Access

    Mutational analysis ofBRCA1andBRCA2genes in Peruvian families with hereditary breast and ovarian cancer

    by Jose Buleje, Maria Guevara-Fujita, Oscar Acosta, Francia D. P. Huaman, Pierina Danos, Alexis Murillo, Joseph A. Pinto, Jhajaira M. Araujo, Alfredo Aguilar, Jaime Ponce, et al.

    Background Breast cancer is one of the most prevalent malignancies in the world. In Peru, breast cancer is the second cause of death among women. Five to ten percent of patients present a high genetic predisposition due to BRCA1 and BRCA2 germline mutations. Methods We performed a comprehensive analysis of BRCA1 and BRCA2 genes by Sanger sequencing and multiplex ligation‐dependent probe amplification (MLPA) to detect large rearrangements in patients from 18 families, which met the criteria for hereditary breast cancer. Results In this series, we found four pathogenic mutations, three previously reported (BRCA1: c.302‐1G>C and c.815_824dup10; BRCA2: c.5946delT) and a duplication of adenines in exon 15 in BRCA1 gene (c.4647_4648dupAA, ClinVar SCV000256598.1). We also found two exonic and four intronic variants of unknown significance and 28 polymorphic variants. Conclusion This is the first report to determine the spectrum of mutations in the BRCA1/BRCA2 genes in Peruvian families selected by clinical and genetic criteria. The alteration rate in BRCA1/BRCA2 with proven pathogenic mutation was 22.2% (4 out 18) and this finding could be influenced by the reduced sample size or clinical criteria. In addition, we found three known BRCA1/BRCA2 mutations and a BRCA1 c.4647_4648dupAA as a novel pathogenic mutation.